Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 255 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Nilda Mesa sold 255 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Nilda Mesa also recently made the following trade(s):

• On Friday, November 8th, Nilda Mesa sold 224 shares of United Therapeutics stock. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72.

United Therapeutics Trading Down 1.3 %

NASDAQ UTHR opened at $352.84 on Thursday. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock’s 50 day moving average is $370.07 and its 200 day moving average is $349.90. The stock has a market cap of $15.75 billion, a PE ratio of 15.50, a P/E/G ratio of 1.05 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.38 earnings per share. On average, analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently made changes to their positions in the company. LSV Asset Management grew its holdings in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after buying an additional 436,851 shares in the last quarter. World Investment Advisors LLC purchased a new position in shares of United Therapeutics in the third quarter valued at $139,206,000. FMR LLC increased its position in United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares during the last quarter. Assetmark Inc. raised its stake in United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after purchasing an additional 152,249 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research reports. LADENBURG THALM/SH SH raised their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. HC Wainwright boosted their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Jefferies Financial Group raised their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. The Goldman Sachs Group upped their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.